Noden Pharma DAC
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Noden Pharma DAC
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Daiichi teams with Glycotope on an antibody-drug conjugate for cancer, while Alector will partner with AbbVie to research antibody targets for Alzheimer’s disease.
A review of biopharma start-up dealmaking and financing from April through June 2016, based on data from Strategic Transactions.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Noden USA
- PDL BioPharma, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.